1
|
Heldman MR, Ahmed AA, Liu W, Vo A, Keane-Candib J, Stevens-Ayers T, Boeckh M, Blauwkamp TA, Fisher CE, Hill JA. Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant. J Infect Dis 2024; 229:576-587. [PMID: 37405403 DOI: 10.1093/infdis/jiad255] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 06/22/2023] [Accepted: 07/03/2023] [Indexed: 07/06/2023] Open
Abstract
BACKGROUND Plasma microbial cell-free DNA sequencing (mcfDNA-Seq) is a noninvasive test for microbial diagnosis of invasive mold infection (IMI). The utility of mcfDNA-Seq for predicting IMI onset and the clinical implications of mcfDNA concentrations are unknown. METHODS We retrospectively tested plasma from hematopoietic cell transplant (HCT) recipients with pulmonary IMI and ≥1 mold identified by mcfDNA-Seq in plasma collected within 14 days of clinical diagnosis. Samples collected from up to 4 weeks before and 4 weeks after IMI diagnosis were evaluated using mcfDNA-Seq. RESULTS Thirty-five HCT recipients with 39 IMIs (16 Aspergillus and 23 non-Aspergillus infections) were included. Pathogenic molds were detected in 38%, 26%, 11%, and 0% of samples collected during the first, second, third, and fourth week before clinical diagnosis, respectively. In non-Aspergillus infections, median mcfDNA concentrations in samples collected within 3 days of clinical diagnosis were higher in infections with versus without extrapulmonary spread (4.3 vs 3.3 log10 molecules per microliter [mpm], P = .02), and all patients (8/8) with mcfDNA concentrations >4.0 log10 mpm died within 42 days after clinical diagnosis. CONCLUSIONS Plasma mcfDNA-Seq can identify pathogenic molds up to 3 weeks before clinical diagnosis of pulmonary IMI. Plasma mcfDNA concentrations may correlate with extrapulmonary spread and mortality in non-Aspergillus IMI.
Collapse
Affiliation(s)
- Madeleine R Heldman
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA
| | | | - Winnie Liu
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Alythia Vo
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | | | - Terry Stevens-Ayers
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Michael Boeckh
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | | | - Cynthia E Fisher
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Joshua A Hill
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| |
Collapse
|
2
|
Wu J, Song W, Yan H, Luo C, Hu W, Xie L, Shen N, Cao Q, Mo X, An K, Tao Y. Metagenomic next-generation sequencing in detecting pathogens in pediatric oncology patients with suspected bloodstream infections. Pediatr Res 2024; 95:843-851. [PMID: 37857845 PMCID: PMC10899103 DOI: 10.1038/s41390-023-02776-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 06/26/2023] [Accepted: 07/17/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND Studies on mNGS application in pediatric oncology patients, who are at high risk of infection, are quite limited. METHODS From March 2020 to June 2022, a total of 224 blood samples from 195 pediatric oncology patients who were suspected as bloodstream infections were enrolled in this study. Their clinical and laboratory data were retrospectively reviewed, and the diagnostic performance of mNGS was assessed. RESULTS Compared to the reference tests, mNGS showed significantly higher sensitivity (89.8% vs 32.5%, P < 0.001) and clinical agreement (76.3% vs 51.3%, P < 0.001) in detecting potential pathogens and distinguishing BSI from non-BSI. Especially, mNGS had an outstanding performance for virus detection, contributing to 100% clinical diagnosed virus. Samples from patients with neutropenia showed higher incidence of bacterial infections (P = 0.035). The most identified bacteria were Escherichia coli, and the overall infections by gram-negative bacteria were significantly more prevalent than those by gram-positive ones (90% vs 10%, P < 0.001). Overall, mNGS had an impact on the antimicrobial regimens' usage in 54.3% of the samples in this study. CONCLUSIONS mNGS has the advantage of rapid and effective pathogen diagnosis in pediatric oncology patients with suspected BSI, especially for virus. IMPACT Compared with reference tests, mNGS showed significantly higher sensitivity and clinical agreement in detecting potential pathogens and distinguishing bloodstream infections (BSI) from non-BSI. mNGS is particularly prominent in clinical diagnosed virus detection. The incidence of bacterial infection was higher in patients with neutropenia, and the overall infection rate of Gram-negative bacteria was significantly higher than that of Gram-positive bacteria. mNGS affects the antimicrobial regimens' usage in more than half of patients.
Collapse
Affiliation(s)
- Jing Wu
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Wenting Song
- Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hui Yan
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chengjuan Luo
- Department of Hematology and Oncology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Wenting Hu
- Department of Hematology and Oncology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Li Xie
- Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Nan Shen
- Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Cao
- Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Xi Mo
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Kang An
- Department of Hematology and Oncology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Yue Tao
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| |
Collapse
|
3
|
Hill JA, Park SY, Gajurel K, Taplitz R. A Systematic Literature Review to Identify Diagnostic Gaps in Managing Immunocompromised Patients With Cancer and Suspected Infection. Open Forum Infect Dis 2024; 11:ofad616. [PMID: 38221981 PMCID: PMC10787371 DOI: 10.1093/ofid/ofad616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 12/05/2023] [Indexed: 01/16/2024] Open
Abstract
Patients with cancer are increasingly vulnerable to infections, which may be more severe than in the general population. Improvements in rapid and timely diagnosis to optimize management are needed. We conducted a systematic literature review to determine the unmet need in diagnosing acute infections in immunocompromised patients with cancer and identified 50 eligible studies from 5188 records between 1 January 2012 and 23 June 2022. There was considerable heterogeneity in study designs and parameters, laboratory methods and definitions, and assessed outcomes, with limited evaluation of diagnostic impact on clinical outcomes. Culture remains the primary diagnostic strategy. Fewer studies employing molecular technologies exist, but emerging literature suggests that pathogen-agnostic molecular tests may add to the diagnostic armamentarium. Well-designed clinical studies using standardized methodologies are needed to better evaluate performance characteristics and clinical and economic impacts of emerging diagnostic techniques to improve patient outcomes.
Collapse
Affiliation(s)
- Joshua A Hill
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Sarah Y Park
- Medical Affairs, Karius, Inc, Redwood City, California, USA
| | - Kiran Gajurel
- Division of Infectious Diseases, Carolinas Medical Center, Atrium Health, Charlotte, North Carolina, USA
| | - Randy Taplitz
- Department of Medicine, City of Hope National Medical Center, Duarte, California, USA
| |
Collapse
|
4
|
Jin D, Le J, Yang Q, Cai Q, Dai H, Luo L, Tong J, Shu W. Pneumocystis jirovecii with high probability detected in bronchoalveolar lavage fluid of chemotherapy-related interstitial pneumonia in patients with lymphoma using metagenomic next-generation sequencing technology. Infect Agent Cancer 2023; 18:80. [PMID: 38057898 DOI: 10.1186/s13027-023-00556-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 11/09/2023] [Indexed: 12/08/2023] Open
Abstract
BACKGROUND Previous studies achieved low microbial detection rates in lymphoma patients with interstitial pneumonia (IP) after chemotherapy. However, the metagenomic next-generation sequencing (mNGS) is a comprehensive approach that is expected to improve the pathogen identification rate. Thus far, reports on the use of mNGS in lymphoma patients with chemotherapy-related IP remain scarce. In this study, we summarized the microbial detection outcomes of lymphoma patients with chemotherapy-related IP through mNGS testing of bronchoalveolar lavage fluid (BALF). METHODS Fifteen lymphoma patients with chemotherapy-related IP were tested for traditional laboratory microbiology, along with the mNGS of BALF. Then, the results of mNGS and traditional laboratory microbiology were compared. RESULTS Of the 15 enrolled patients, 11 received rituximab and 8 were administered doxorubicin hydrochloride liposome. The overall microbial yield was 93.3% (14/15) for mNGS versus 13.3% (2/15) for traditional culture methods (P ≤ 0.05). The most frequently detected pathogens were Pneumocystis jirovecii (12/15, 80%), Cytomegalovirus (4/15, 26.7%), and Epstein-Barr virus (3/15, 20%). Mixed infections were detected in 10 cases. Five patients recovered after the treatment with antibiotics alone without glucocorticoids. CONCLUSION Our findings obtained through mNGS testing of BALF suggested a high microbial detection rate in lymphoma patients with IP after chemotherapy. Notably, there was an especially high detection rate of Pneumocystis jirovecii. The application of mNGS in patients with chemotherapy-related IP was more sensitive.
Collapse
Affiliation(s)
- Dian Jin
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Jing Le
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Qianqian Yang
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Qianqian Cai
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Hui Dai
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Liufei Luo
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Jiaqi Tong
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China
| | - Wenxiu Shu
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, No.1111, Jiangnan road, Ningbo, 315010, China.
| |
Collapse
|
5
|
He Y, Geng S, Mei Q, Zhang L, Yang T, Zhu C, Fan X, Wang Y, Tong F, Gao Y, Fang X, Bao R, Sheng X, Pan A. Diagnostic Value and Clinical Application of Metagenomic Next-Generation Sequencing for Infections in Critically Ill Patients. Infect Drug Resist 2023; 16:6309-6322. [PMID: 37780531 PMCID: PMC10541086 DOI: 10.2147/idr.s424802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 09/14/2023] [Indexed: 10/03/2023] Open
Abstract
Objective To evaluate the diagnostic value and clinical application of metagenomic next-generation sequencing (mNGS) for infections in critically ill patients. Methods Comparison of diagnostic performance of mNGS and conventional microbiological testing for pathogens was analyzed in 234 patients. The differences between immunocompetent and immunocompromised individuals in mNGS-guided anti-infective treatment adjustment were also analyzed. Results The sensitivity and specificity of mNGS for bacterial and fungal detection were 96.6% (95% confidence interval [CI], 93.5%-99.6%) and 83.1% (95% CI, 75.2%-91.1%), and 85.7% (95% CI, 71.9%-99.5%) and 93.2% (95% CI, 89.7%-96.7%), respectively. Overall, 152 viruses were detected by mNGS, but in which 28 viruses were considered causative agents. The proportion of mNGS-guided beneficial anti-infective therapy adjustments in the immunocompromised group was greater than in the immunocompetent group (48.5% vs 30.1%; P=0.008). In addition, mNGS-guided anti-infective regimens with peripheral blood and BALF specimens had the highest proportion (39.0%; 40.0%), but the proportion of patients not helpful due to peripheral blood mNGS was also as high as 22.0%. Conclusion mNGS might be a promising technology to provide precision medicine for critically ill patients with infection.
Collapse
Affiliation(s)
- Yuxi He
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Shike Geng
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Qing Mei
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Lei Zhang
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Tianjun Yang
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Chunyan Zhu
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Xiaoqin Fan
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Yinzhong Wang
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Fei Tong
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Yu Gao
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Xiaowei Fang
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
| | - Renren Bao
- Department of Intensive Care Unit, the Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China
| | - Ximei Sheng
- Department of Intensive Care Unit, the Training Center of Anhui Provincial Hospital, Wannan Medical College, Wuhu, Anhui, People’s Republic of China
| | - Aijun Pan
- Department of Intensive Care Unit, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
- Department of Intensive Care Unit, the Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China
- Department of Intensive Care Unit, the Training Center of Anhui Provincial Hospital, Wannan Medical College, Wuhu, Anhui, People’s Republic of China
| |
Collapse
|
6
|
Lee KH, Won D, Kim J, Lee JA, Kim CH, Kim JH, Jeong SJ, Ku NS, Choi JY, Yeom JS, Cho H, Chung H, Cheong JW, Lee ST, Jang JE, Shin S, Ahn JY. Utility of Plasma Microbial Cell-Free DNA Whole-Genome Sequencing for Diagnosis of Invasive Aspergillosis in Patients With Hematologic Malignancy or COVID-19. J Infect Dis 2023; 228:444-452. [PMID: 37317030 DOI: 10.1093/infdis/jiad213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 05/25/2023] [Accepted: 06/06/2023] [Indexed: 06/16/2023] Open
Abstract
BACKGROUND We evaluated the clinical accuracy and utility of whole-genome sequencing (WGS) of plasma microbial cell-free DNA (cfDNA) as a novel noninvasive method in diagnosing invasive aspergillosis (IA) in patients with hematologic malignancy (HM) or coronavirus disease 2019 (COVID-19). METHODS Adults with HM or COVID-19 and suspected IA were recruited. IA cases were retrospectively diagnosed according to EORTC/MSG definitions and ECMM/ISHAM criteria for HM and COVID-19 patients, respectively. The results of cfDNA WGS were compared with the conventional diagnosis. RESULTS Microbial cfDNA WGS was performed 53 times from 41 participants (19 from HM, 16 from COVID-19, and 7 from the control group). In participants with HM, Aspergillus cfDNA was detected in 100% of proven IA and 91.7% of probable IA cases. In participants with COVID-19, 50.0% of probable IA were positive for Aspergillus in cfDNA WGS. Concordance between Aspergillus cfDNA detection and proven/probable IA conventional diagnosis was significantly higher in participants with HM than in those with COVID-19. IA diagnosed using EORTC/MGS definitions showed significantly high concordance between Aspergillus cfDNA detection and proven/probable IA. CONCLUSIONS Aspergillus cfDNA detection strongly correlated with proven/probable IA diagnosed using EORTC/MSG definitions and could be used as an additional diagnostic tool for IA.
Collapse
Affiliation(s)
- Ki Hyun Lee
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Dongju Won
- Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jinnam Kim
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jung Ah Lee
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Chang Hyup Kim
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jung Ho Kim
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Su Jin Jeong
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Nam Su Ku
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jun Yong Choi
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Joon-Sup Yeom
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Hyunsoo Cho
- Division of Hematology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - Haerim Chung
- Division of Hematology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - June-Won Cheong
- Division of Hematology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - Seung-Tae Lee
- Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Ji Eun Jang
- Division of Hematology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - Saeam Shin
- Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jin Young Ahn
- Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
7
|
Wang G, Long J, Zhuang Y, Leng X, Zhang Y, Liu L, Fu J, Chen Y, Li C, Zhou Y, Huang B, Feng C. Application of metagenomic next-generation sequencing in the detection of pathogens in spinal infections. Spine J 2023; 23:859-867. [PMID: 36773890 DOI: 10.1016/j.spinee.2023.02.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Revised: 01/19/2023] [Accepted: 02/03/2023] [Indexed: 02/13/2023]
Abstract
BACKGROUND CONTEXT The precise diagnosis and treatment of spinal infections (SI) remains challenging for spine surgeons. Identifying the pathogens of SI through metagenomic next-generation sequencing (mNGS) may be a key approach to addressing this challenge. PURPOSE To evaluate the accuracy and applicability of mNGS in determining the etiology of SI. STUDY DESIGN Diagnostic test study. PATIENT SAMPLE Twenty-five patients who had a clinical suspicion of SI and underwent mNGS testing. OUTCOME MEASURES The specificity, sensitivity, and time cost of mNGS and bacterial culture were compared. Clinical outcomes were assessed using the numeric rating scale (NRS) score, Oswestry Disability Index (ODI), and the Japanese Orthopedic Association (JOA) score. Demographic data and laboratory results (blood cell count (WBC), erythrocyte sedimentation rate (ESR), neutrophil percentage (NEUT%), and C-reactive protein level (CRP) were also evaluated. METHODS In this retrospective study, samples were obtained from 25 eligible patients via surgery or CT-guided puncture and subjected to histopathological examination, bacterial culture, and mNGS. The sensitivity and specificity of the bacterial cultures and mNGS were calculated with respect to the histopathological results as a reference. Postoperative antibiotics or antituberculosis drugs were administered on the basis of mNGS results, combined with clinical manifestations, imaging examination, and histopathology. The changes of clinical outcomes and laboratory results after treatment were observed. RESULTS Of the 25 patients, 21 had a positive pathology, of which 10 showed a tuberculous pathology, and the remaining 11 showed a nontuberculous inflammatory pathology. The sensitivity of mNGS was higher than that of the bacterial culture. However, the difference in specificity between bacterial culture and mNGS was not significant. Moreover, the time needed to perform mNGS was significantly lower than that of bacterial culture and pathology. All patients were followed up for more than three months, and CRP and NEUT% significantly decreased by three months after treatment. There was no significant difference in WBC and ESR. The ODI, NRS and JOA scores were significantly improved after treatment. CONCLUSION Metagenomic next-generation sequencing technology can play an important role in the detection of pathogens in SI and should be further investigated and applied in future studies.
Collapse
Affiliation(s)
- Guanzhong Wang
- Department of Orthopedics Southwest Hospital, Army Medical University, Gaotanyan St No.30, Chongqing 400038, People's Republic of China
| | - Jiang Long
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Yong Zhuang
- Department of Orthopedics, Affiliated Hospital of Guizhou Medical University, 28 Guiyi St Yunyan District, Guiyang 550004, People's Republic of China
| | - Xue Leng
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Yaqing Zhang
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Libangxi Liu
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Jiawei Fu
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Yu Chen
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Changqing Li
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Yue Zhou
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Bo Huang
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China
| | - Chencheng Feng
- Department of Orthopedics Xinqiao Hospital, Army Medical University, 183 Xinqiao Main St Shapingba, Chongqing 400037, People's Republic of China.
| |
Collapse
|
8
|
Fishman JA. Next-Generation Sequencing for Identifying Unknown Pathogens in Sentinel Immunocompromised Hosts. Emerg Infect Dis 2023; 29:431-432. [PMID: 36596567 PMCID: PMC9881763 DOI: 10.3201/eid2902.221829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
9
|
Pérot P, Fourgeaud J, Rouzaud C, Regnault B, Da Rocha N, Fontaine H, Le Pavec J, Dolidon S, Garzaro M, Chrétien D, Morcrette G, Molina TJ, Ferroni A, Leruez-Ville M, Lortholary O, Jamet A, Eloit M. Circovirus Hepatitis Infection in Heart-Lung Transplant Patient, France. Emerg Infect Dis 2023; 29:286-293. [PMID: 36596569 PMCID: PMC9881760 DOI: 10.3201/eid2902.221468] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
In March 2022, a 61-year-old woman in France who had received a heart-lung transplant sought treatment with chronic hepatitis mainly characterized by increased liver enzymes. After ruling out common etiologies, we used metagenomic next-generation sequencing to analyze a liver biopsy sample and identified an unknown species of circovirus, tentatively named human circovirus 1 (HCirV-1). We found no other viral or bacterial sequences. HCirV-1 shared 70% amino acid identity with the closest known viral sequences. The viral genome was undetectable in blood samples from 2017-2019, then became detectable at low levels in September 2020 and peaked at very high titers (1010 genome copies/mL) in January 2022. In March 2022, we found >108 genome copies/g or mL in the liver and blood, concomitant with hepatic cytolysis. We detected HCirV-1 transcripts in 2% of hepatocytes, demonstrating viral replication and supporting the role of HCirV-1 in liver damage.
Collapse
Affiliation(s)
| | | | | | - Béatrice Regnault
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Nicolas Da Rocha
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Hélène Fontaine
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Jérôme Le Pavec
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Samuel Dolidon
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Margaux Garzaro
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Delphine Chrétien
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Guillaume Morcrette
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Thierry Jo Molina
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Agnès Ferroni
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Marianne Leruez-Ville
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | | | | | | |
Collapse
|
10
|
Walti CS, Halpern AB, Xie H, Kiem ES, Chung EL, Schonhoff KG, Huebner EM, Delaney C, Liu C, Pergam SA, Cheng GS, Kimball LE, Leisenring WM, Boeckh M, Walter RB, Hill JA. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 2023; 37:298-307. [PMID: 36509892 DOI: 10.1038/s41375-022-01786-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2022] [Revised: 11/30/2022] [Accepted: 12/02/2022] [Indexed: 12/14/2022]
Abstract
Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone ("CLAG-M") may result in higher remission rates than standard-dose cytarabine plus anthracycline ("7 + 3") but may result in more infections. We compared moderate to severe infections occurring up to 90 days after the first induction cycle for AML or other high-grade myeloid neoplasms in patients receiving CLAG-M for newly diagnosed (n = 196) or relapsed/refractory disease (n = 131) or 7 + 3 for newly diagnosed disease (n = 115). For newly diagnosed disease, microbiologically documented infections were more frequent after CLAG-M compared to 7 + 3 (adjusted rate ratio, 1.65 [95% CI, 1.06-2.58]; P = 0.03), with a cumulative incidence of 27.8% and 16.5% by day 90, respectively. Patients receiving CLAG-M for relapsed/refractory disease had the highest cumulative incidence of 50.7%. Bacterial bloodstream infections were the most frequent followed by respiratory tract infections. Among 29 patients (7%) who died, infection was a primary or contributing cause of death in 59%. These data indicate that infections continue to cause substantial morbidity in patients treated for AML, especially those treated for relapsed/refractory disease, and are more common with newer, more myelosuppressive regimens such as CLAG-M. Improved strategies for infection prevention are needed.
Collapse
|
11
|
Shen D, Zhou B, Shan M, Li X, Chu M, Shen Y, Zhan Y, Xu J, Wu D, Xu Y. Evaluation of the Diagnostic Performance of Plasma Metagenomic Next-Generation Sequencing in Febrile Events in the First 30 Days after Chimeric Antigen Receptor T Cell Infusion. Transplant Cell Ther 2023; 29:304.e1-304.e8. [PMID: 36724855 DOI: 10.1016/j.jtct.2023.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 01/21/2023] [Accepted: 01/23/2023] [Indexed: 01/30/2023]
Abstract
Chimeric antigen receptor-modified T cell (CAR-T) therapy is a promising novel immunotherapy for hematologic malignancies, and the diagnosis of infection after CAR-T infusion (CTI) presents challenges for clinicians. Plasma metagenomic next-generation sequencing (mNGS) has been shown to be a reliable diagnostic approach for infection, especially in immunocompromised patients. We aimed to investigate the diagnostic performance of plasma mNGS for infection in the first 30 days after CTI. A cohort of 153 patients who experienced a total of 170 febrile events during the first 30 days post-CTI were enrolled. Of these events, 51 were evaluated with both mNGS and CDM and 119 were assessed by conventional detection methods (CDM) only. We also explored the epidemiology of infections and differences in infection complications in cases with severe (>2) and moderate (≤2) cytokine release syndrome (CRS). Cases with febrile events were clinically divided into an infection group (IG) (95 of 170; 55.9%) and a noninfection group (NIG) (75 of 170; 44.1%). The sensitivity and specificity of mNGS for the diagnosis of infectious complications in the first 30 days after CTI were 69.2% and 89.2%, respectively, with the sensitivity superior to that of culture (P < .001). More infection cases assessed with both mNGS and CDM than those assessed with CDM only were laboratory-confirmed (63.9% versus 11.9%; P < .001). The serum C-reactive protein level was higher and the IFN-γ level was lower in the IG group, particularly in cases with CRS grade ≤2. Infection is a common complication in the first 30 days after CTI. The addition of mNGS to CDM improved the diagnostic yield, and mNGS showed relatively high sensitivity and specificity in post-CAR-T therapy febrile events.
Collapse
Affiliation(s)
- Danya Shen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Biqi Zhou
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Meng Shan
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Xuekai Li
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Mengqian Chu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Yifan Shen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Yuchen Zhan
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
| | - Jie Xu
- Center of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.
| | - Depei Wu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
| | - Yang Xu
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
| |
Collapse
|
12
|
Husson J, Bork JT, Morgan D, Baddley JW. Is diagnostic stewardship possible in solid organ transplantation? Transpl Infect Dis 2022; 24:e13899. [DOI: 10.1111/tid.13899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Accepted: 06/08/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Jennifer Husson
- Institute of Human Virology Department of Medicine University of Maryland School of Medicine Baltimore Maryland USA
| | - Jacqueline T. Bork
- Department of Medicine University of Maryland School of Medicine and VA Maryland Healthcare System Baltimore Maryland USA
| | - Daniel Morgan
- Department of Epidemiology and Public Health VA Maryland Healthcare System University of Maryland School of Medicine Baltimore Maryland USA
| | - John W. Baddley
- Department of Medicine University of Maryland School of Medicine and VA Maryland Healthcare System Baltimore Maryland USA
| |
Collapse
|
13
|
Deng Q, Cao Y, Wan X, Wang B, Sun A, Wang H, Wang Y, Wang H, Gu H. Nanopore-based metagenomic sequencing for the rapid and precise detection of pathogens among immunocompromised cancer patients with suspected infections. Front Cell Infect Microbiol 2022; 12:943859. [PMID: 36204638 PMCID: PMC9530710 DOI: 10.3389/fcimb.2022.943859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Accepted: 08/22/2022] [Indexed: 11/16/2022] Open
Abstract
Cancer patients are at high risk of infections and infection-related mortality; thereby, prompt diagnosis and precise anti-infectives treatment are critical. This study aimed to evaluate the performance of nanopore amplicon sequencing in identifying microbial agents among immunocompromised cancer patients with suspected infections. This prospective study enlisted 56 immunocompromised cancer patients with suspected infections. Their body fluid samples such as sputum and blood were collected, and potential microbial agents were detected in parallel by nanopore amplicon sequencing and the conventional culture method. Among the 56 body fluid samples, 47 (83.9%) samples were identified to have at least one pathogen by nanopore amplicon sequencing, but only 25 (44.6%) samples exhibited a positive finding by culture. Among 31 culture-negative samples, nanopore amplicon sequencing successfully detected pathogens in 22 samples (71.0%). Nanopore amplicon sequencing showed a higher sensitivity in pathogen detection than that of the conventional culture method (83.9% vs. 44.6%, P<0.001), and this advantage both existed in blood samples (38.5% vs. 0%, P=0.039) and non-blood samples (97.7% vs. 58.1%, P<0.001). Compared with the culture method, nanopore amplicon sequencing illustrated more samples with bacterial infections (P<0.001), infections from fastidious pathogens (P=0.006), and co-infections (P<0.001). The mean turnaround time for nanopore amplicon sequencing was about 17.5 hours, which was shorter than that of the conventional culture assay. This study suggested nanopore amplicon sequencing as a rapid and precise method for detecting pathogens among immunocompromised cancer patients with suspected infections. The novel and high-sensitive method will improve the outcomes of immunocompromised cancer patients by facilitating the prompt diagnosis of infections and precise anti-infectives treatment.
Collapse
Affiliation(s)
- Qingmei Deng
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Science Island Branch, Graduate School of University of Science and Technology of China, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
| | - Yongqing Cao
- The Cancer Hospital of the University of Chinese Academy of Sciences, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China
| | - Xiaofeng Wan
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
| | - Bin Wang
- Zhejiang ShengTing Biotechnology Company, Hangzhou, China
| | - Aimin Sun
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
| | - Huanzhong Wang
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
| | - Yunfei Wang
- Zhejiang ShengTing Biotechnology Company, Hangzhou, China
| | - Hongzhi Wang
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Science Island Branch, Graduate School of University of Science and Technology of China, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
- *Correspondence: Hongzhi Wang, ; Hongcang Gu,
| | - Hongcang Gu
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, China
- Science Island Branch, Graduate School of University of Science and Technology of China, Hefei, China
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China
- *Correspondence: Hongzhi Wang, ; Hongcang Gu,
| |
Collapse
|
14
|
Li W, Zhu H, Wen L, Quan M, Wang L. Application Value of Metagenomics Next-Generation Sequencing (mNGS) in Detection of Mucormycosis after Chemotherapy in Childhood Acute Leukemia. Evid Based Complement Alternat Med 2022; 2022:7366432. [PMID: 36034963 PMCID: PMC9417758 DOI: 10.1155/2022/7366432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 07/15/2022] [Indexed: 11/18/2022]
Abstract
Objective To analyze the application of macrogenomics next-generation sequencing (mNGS) in the detection of postchemotherapy trichomoniasis cases in children with acute leukemia. Methods To retrospectively analyze the clinical data of 7 patients with acute leukemia combined with trichomoniasis after chemotherapy in the department of hematology and oncology of Hebei Children's Hospital, and to summarize the characteristics of their postchemotherapy clinical data, diagnostic and therapeutic processes, and outcomes. Results Among the 7 children, 6 cases had acute lymphoblastic leukemia and 1 case had acute myeloid leukemia. mNGS detected trichoderma infection, including 1 case of pulmonary cerebral type and 6 cases of pulmonary type. After treatment, 1 case died, 2 cases were cured, and 4 cases improved. Conclusion The clinical manifestations of trichomoniasis after combined chemotherapy in pediatric acute leukemia lack specificity. Early application of the mNGS assay is of great value.
Collapse
Affiliation(s)
- Wenzi Li
- Department of Hematology and Oncology, Hebei Province Children's Hospital, Shijiazhuang City 050031, Hebei Province, China
| | - Hua Zhu
- Hebei Province Children's Hospital Orthopedics Department, Shijiazhuang City 050031, Hebei Province, China
| | - Li Wen
- Department of Hematology and Oncology, Hebei Province Children's Hospital, Shijiazhuang City 050031, Hebei Province, China
| | - Meijie Quan
- Department of Hematology and Oncology, Hebei Province Children's Hospital, Shijiazhuang City 050031, Hebei Province, China
| | - Li Wang
- Department of Hematology and Oncology, Hebei Province Children's Hospital, Shijiazhuang City 050031, Hebei Province, China
| |
Collapse
|
15
|
Fan S, Si M, Xu N, Yan M, Pang M, Liu G, Gong J, Wang H. Metagenomic next-generation sequencing-guided antimicrobial treatment versus conventional antimicrobial treatment in early severe community-acquired pneumonia among immunocompromised patients (MATESHIP): A study protocol. Front Microbiol 2022; 13:927842. [PMID: 35983331 PMCID: PMC9379097 DOI: 10.3389/fmicb.2022.927842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 07/07/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundSevere community-acquired pneumonia (SCAP) is the main cause of mortality in immunocompromised patients. Compared with conventional microbiological tests (CMT), metagenomic next-generation sequencing (mNGS) can quickly and simultaneously detect a wide array of bacteria, viruses, and fungi in an unbiased manner. It is increasingly used for severe respiratory infectious diseases, especially for immunocompromised patients. However, the effects of mNGS-based antimicrobial treatment procedures on clinical outcomes in immunocompromised patients with SCAP have not been evaluated.Methods/DesignThe MATESHIP study is a prospective, multicenter, parallel-group, open-label, randomized controlled trial from 20 ICUs in university hospitals and academic teaching hospitals across Shandong Province, China. We will enroll 342 immunocompromised patients with early onset SCAP who are admitted to an intensive care unit (ICU). Participants will be randomly allocated to an mNGS-guided treatment group or a conventional treatment group (guided by CMT), according to centrally computer-based block randomization stratified by participating centers. Participants will undergo CMT tests using appropriate lower respiratory tract (LRT) and other necessary specimens, with or without mNGS tests using LRT specimens. The primary outcomes will be: (1) The relative change in Sequential Organ Failure Assessment (SOFA) score from randomization to day 5, day 7, day 10, or the day of ICU discharge/death; and (2) the consumption of antimicrobial agents during ICU stay (expressed as defined daily doses). The secondary outcome measures will be: days from randomization to initiation of definitive antimicrobial treatment; overall antimicrobial agent use and cost; total cost of hospitalization; length of ICU stay; 28- and 90-day mortality; and clinical cure rate. This study hypothesizes that mNGS-guided treatment will decrease the degree of organ dysfunction/failure, the consumption of antimicrobial agents, and mortality, while the cure rate will be increased, and the time to initiation of appropriate therapy will be advanced.DiscussionThe MATESHIP study will evaluate for the first time whether mNGS-guided antimicrobial therapy improves the outcomes of SCAP in an immunocompromised population, and provide high-level evidence on the application of mNGS in the management of this population.Clinical Trial Registration[ClinicalTrials.gov], identifier [NCT05290454].
Collapse
Affiliation(s)
- Shaohua Fan
- Department of Critical Care Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Min Si
- Department of Critical Care Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Nana Xu
- Department of Cardiac Surgery, Cardiac Surgery Care Unit, Qilu Hospital of Shandong University, Jinan, China
| | - Meichen Yan
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Mingmin Pang
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Guangfeng Liu
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Jibin Gong
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Hao Wang
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
- *Correspondence: Hao Wang,
| |
Collapse
|